Title Page

Title: Attenuation of cocaine’s reinforcing and discriminative stimulus effects via muscarinic M₁ acetylcholine receptor stimulation

Authors: Morgane Thomsen, P. Jeffrey Conn, Craig Lindsley, Jürgen Wess, Joon Y. Boon, Brian S. Fulton, Anders Fink-Jensen, and S. Barak Caine

Primary laboratory of origin: Alcohol and Drug Abuse Research Center, McLean Hospital / Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA (MT, JYB, BSF, SBC).

Vanderbilt Program in Drug Discovery, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 (PJC, CL).

Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA (JW).

Laboratory of Neuropsychiatry, University of Copenhagen and Psychiatric Center Rigshospitalet, Copenhagen University Hospitals, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark (AFJ).
Running Title Page

a) Running Title: Anti-cocaine effects of muscarinic M₁ receptor stimulation

b) Corresponding author: Morgane Thomsen

Alcohol and Drug Abuse Research Center
McLean Hospital / Harvard Medical School
115 Mill Street, Belmont, MA 02478, USA
Phone 617 855 3285
Fax 617 855 3865
e-mail mthomsen@mclean.harvard.edu

c) - number of text pages: 28 (incl. abstract, references, figure legends, tables)
   - number of tables: 4
   - number of figures: 9
   - number of references: 43
   - number of words in the Abstract: 247
   - number of words in the Introduction: 750
   - number of words in the Discussion: 1499 words

d) Nonstandard abbreviations: - FR: fixed ratio
   - DAR: drug-appropriate responding
   - VTA: ventral tegmental area
   - NAc: nucleus accumbens
   - i.v.: intravenous/intravenously
   - A₅₀: dose that produced 50% effect

e) A recommended section assignment: Behavioral pharmacology
Abstract

Muscarinic cholinergic receptors modulate dopaminergic function in brain pathways thought to mediate cocaine’s abuse-related effects. Here we sought to confirm and extend in the mouse species findings that nonselective muscarinic receptor antagonists can enhance cocaine’s discriminative stimulus. More importantly, we tested the hypothesis that muscarinic receptor agonists with varied receptor subtype selectivity can blunt cocaine’s discriminative stimulus and reinforcing effects; we hypothesized a critical role for the M₁ and/or M₄ receptor subtypes in this modulation. Mice were trained to discriminate cocaine from saline, or to self-administer intravenous cocaine chronically. The non-selective muscarinic antagonists scopolamine and methylscopolamine, the non-selective muscarinic agonists oxotremorine and pilocarpine, the M₁/M₄-preferring agonist xanomeline, the putative M₁-selective agonist McN-A-343, and the novel M₁-selective agonist TBPB were tested as substitution and/or pretreatment to cocaine. Both muscarinic antagonists partially substituted for cocaine and enhanced its discriminative stimulus. Conversely, muscarinic agonists blunted cocaine discrimination and abolished cocaine self-administration with varying effects on food-maintained behavior. Specifically, increasing selectivity for the M₁ subtype (oxotremorine < xanomeline < TBPB) conferred lesser nonspecific rate-suppressing effects, with no rate suppression for TBPB. In mutant mice lacking M₁ and M₄ receptors, xanomeline failed to diminish cocaine discrimination while rate-decreasing effects were intact. Our data suggest that central M₁ receptor activation attenuates cocaine’s abuse-related effects, while non-M₁/M₄ receptors likely contribute to undesirable effects of muscarinic stimulation. These data provide the first demonstration of anti-cocaine effects of systemically applied, M₁ receptor agonists and suggest the possibility of a new approach to pharmacotherapy for cocaine addiction.
Introduction

Cocaine and other stimulant abuse is a considerable public health problem, for which no established pharmacotherapy is available. Mounting evidence suggests cholinergic systems are implicated in abuse-related effects of cocaine and other abused drugs. The reinforcing effects of cocaine depend upon dopamine systems that arise in the ventral tegmental area (VTA) and project to the nucleus accumbens (NAc; Roberts et al., 1980). Dopamine release in these pathways is regulated by cholinergic input through muscarinic receptors (Oakman et al., 1995; Blaha et al., 1996). In addition, muscarinic receptors within the striatum (including the NAc) co-localize with dopamine receptors and modulate neuronal responses to dopamine receptor activation. Specifically, $M_4$ and $D_1$ receptors exert directly opposing effects on cyclic AMP synthesis, while $M_1$ receptors oppose the effects of $D_2$ receptors (Di Chiara et al., 1994; Onali & Olianas, 2002). Systemic administration of muscarinic antagonists induce striatal dopamine release in humans and rats, and was found to potentiate cocaine-induced dopamine increases in rats (Dewey et al., 1993; Chapman et al., 1997; Tanda et al., 2007). Conversely, muscarinic agonists produce functional dopamine antagonism (Bymaster et al., 1998). Based on the above-mentioned interactions with dopamine receptors, the $M_1$ and $M_4$ receptors appear most likely to mediate this functional dopamine antagonism.

Most studies investigating effects of cholinergic manipulations on rewarded behaviors have focused on the roles of specific brain regions, rather than on systemic pharmacological manipulations. In rats, immunotoxic destruction of cholinergic neurons in the NAc increased the potency of self-administered cocaine, while intra-NAc infused oxotremorine, a muscarinic agonist, reduced cocaine self-administration (Smith et al., 2004; Mark et al., 2006). Those findings indicate stimulation of NAc muscarinic receptors opposes the reinforcing effects of cocaine. In contrast to the NAc, the non-selective cholinergic agonist carbachol produced conditioned place preference and was self-administered when infused into the VTA (Ikemoto & Wise, 2002). Experimenter-induced elevation of acetylcholine levels in the VTA similarly reinstated lever pressing in rats trained to self-administer cocaine, by a mechanism dependent on muscarinic receptors (You et al., 2008). Intra-VTA infusions of muscarinic antagonists opposed cocaine self-administration and blunted its effect on extracellular VTA dopamine (You et al., 2008). Lesions of the
pedunculopontine tegmental nucleus were similarly shown to reduce amphetamine reward (Bechara &
vander Kooy, 1989; Alderson et al., 2004). Thus muscarinic receptors in the VTA and pedunculopontine
tegmental nucleus appear to facilitate drug reward. Those facilitations are most likely dependent on M₅
receptors, (Forster et al., 2002; Thomsen et al., 2005), although recent studies indicate that M₅ receptors
may modulate effects of different drugs of abuse differentially (Schmidt et al., 2010) and other brain
regions and muscarinic receptors may also facilitate abuse-related effects of drugs (Carrigan et al., 2007;
Crespo et al., 2006).

Because of the opposing effects of muscarinic receptors in different brain regions, one cannot easily
generalize from the above studies what effects systemic administration of muscarinic ligands would have.
While studies targeting specific brain sites are important to help us understand the biology of addiction
disorders, it is most likely that pharmacotherapy in humans will be given systemically. Most studies
investigating the effect of systemically administered muscarinic ligands on behavioral effects of cocaine
have focused on antagonists, generally showing enhancement of cocaine’s effects (Wilson & Schuster,
There are few reports on modulation of cocaine’s effects by systemically applied muscarinic agonists or
acetylcholinesterase inhibitors. In a single-session tail-vein self-administration procedure in mice,
muscarinic agonists decreased rates of cocaine self-administration (Rasmussen et al., 2000). However,
because the pretreatments were tested against the peak dose of cocaine, it is difficult to ascertain
whether this decrease in response rates reflected a leftward or rightward shift in cocaine’s dose-effect
function. In addition, non-specific rate-decreasing effects of the pretreatments could have contributed to
those findings. Acetylcholinesterase inhibitor treatment prevented the development of conditioned place
preference to both morphine and cocaine and decreased cocaine self-administration (Hikida et al., 2003;
Grasing et al., 2009). However, the clinical usefulness of acetylcholinesterase inhibitors and non-selective
muscarinic agonists may be limited by opposing effects at different receptor subtypes, and by well-
recognized adverse effects (e.g., nausea). Finally, hypercholinergic rats showed a blunted response to
cocaine (Fagergren et al., 2005). Here we tested the hypothesis that systemically administered
muscarinic agonists would attenuate abuse-related effects of cocaine. We further hypothesized that
selectivity for M₁ or M₁/M₄ subtypes would confer greater effectiveness and lower risk of adverse effects.
We tested various muscarinic ligands, including the novel M₁-selective allosteric agonist TBPB (Jones et al., 2008), in a cocaine discrimination procedure and a chronic cocaine self-administration procedure in mice.
Methods

Animals and housing. Male Swiss Webster mice, male wild-type C57BL/6NTac and male M₁⁻/⁻-M₄⁻/⁻ mice were bred at Taconic Farms (Germantown, NY) and were acquired at 4-8 weeks of age. M₁⁻/⁻ and M₄⁻/⁻ mice were generated as described previously using 129S6/SvEv embryonic stem cells (Gomeza et al., 1999; Miyakawa et al., 2001) and backcrossed 11 generations to C57BL/6NTac females to produce essentially congenic mice. Double knockout mice were bred by intercrossing the single knockout lines and then maintained as a separate line, due to the low yield of double knockout mice if bred by heterozygous intermating. Age- and sex-matched C57BL/6NTac mice were thus used as wild-type controls. Animals were acclimated to the housing facilities at least 7 days before experiments were initiated. During this time they were also handled, and were anesthetized briefly once for subcutaneous implantation of an identification microchip. Animals were kept in a 12-h light/dark cycle at ~22°C and ~55% humidity, group housed up to 5 per cage. Water was accessible ad libitum and standard rodent chow (rodent diet 5001, PMI Feeds, Inc., St. Louis, MO) was provided once daily after training/testing sessions, 4g/mouse/day. For enrichment, rodent “treats”, nesting material and hiding/nesting devices were provided. Running wheels were available, although before catheter implantation only in the self-administration groups, to avoid potential injuries caused by the protruding catheter base. All testing was conducted during the light phase of the circadian cycle. All procedures were carried out in accordance with NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee.

Operant conditioning apparatus. The same type of apparatus was used for drug discrimination and self-administration, but distinct equipment was dedicated to each assay. Operant conditioning chambers as well as training and evaluation of food-maintained behavior under a fixed ratio (FR) schedule of reinforcement have been described in detail (Thomsen & Caine, 2005). Briefly, each operant conditioning chamber contained two nose-poke holes 10 mm above the grid floor, each equipped with a photocell and a yellow cue light. Centered between the holes was a plate into which liquid food could be delivered. For self-administration, a liquid swivel mounted on a balance arm was used for i.v. drug delivery in the freely moving animals.
Training and evaluation in cocaine discrimination. Mice were trained to discriminate 10 mg/kg cocaine from saline, administered i.p. 10 min prior to the session. Liquid food (25 µl Ensure® protein drink, vanilla) was used as the reinforcer, with a maximum of 30 reinforcers available per 20-min session. Mice were trained initially under a FR 1 schedule, with the 10-min pretreatment time spent in the home cage, to ensure that the first nose-pokes were reinforced. The FR was then gradually increased to a final FR 10, and longer portions of the pretreatment time were spent in the operant conditioning chamber. Final sessions were preceded by a 10-min pretreatment period in the chamber, during which all lights were off and responding had no scheduled consequences. Cocaine and saline were presented in pseudorandom order, and mice were counterbalanced with cocaine trained on the left or right hole. Criteria for stable discrimination were met when at least 7 of 8 consecutive session satisfied: (1) ≥10 reinforcers earned per session, (2) ≥80% correct responses for the first reinforcer and ≥90% correct total responses.

After criteria were met, mice were tested with saline and 0.32-18 mg/kg cocaine to generate dose-effect functions. In substitution tests, amphetamine (0.1-1.8 mg/kg), U-50488 (3.2-18 mg/kg), scopolamine (0.032-56 mg/kg) or methylscopolamine (1-56 mg/kg) was administered i.p. immediately before placing the animal in the test chamber. For drug combinations, 0.32 mg/kg scopolamine or 1 mg/kg methylscopolamine was added to cocaine solutions of each dose, and administered as substitutions. In pretreatment tests, oxotremorine (0.032-0.18 mg/kg) was administered s.c. 20 min before cocaine, pilocarpine (1-10 mg/kg) s.c. 30 min before cocaine, xanomeline (0.32-3.2 mg/kg) s.c. 15 min before cocaine, McN-A-343 (3.2-18 mg/kg) s.c. immediately before cocaine, and TBPB (18-100 mg/kg) i.p. 30 min before cocaine. For each drug including cocaine, doses were tested within-subjects according to a Latin square design. At least one training session was interspersed between each test session, and tests were only performed when mice satisfied discrimination criteria.

Training and evaluation of cocaine self-administration. Training and evaluation of food-maintained behavior and cocaine self-administration under a FR 1 schedule have been described elsewhere (Caine et al., 2002; Thomsen & Caine, 2005). Responding in the right-sided hole resulted in delivery of a reinforcer and turning on of the cue light for 20 sec during which no reinforcer could be earned (i.e., postreinforcer timeout). Cocaine solutions or saline was delivered in 0.56 ml/kg doses, e.g., for a 32-g mouse, 18 µl infused over 3.2 s. Responses in the left-sided hole were counted but had no scheduled
consequences. At the start of sessions, a single noncontingent reinforcer was delivered, then the house light was turned on, and remained illuminated until the end of the session. The mice were initially trained with liquid food (Ensure®, vanilla): mice were placed in the operant conditioning chamber daily for 2-h sessions, 5 days/week. The mice were allowed at least 5 consecutive sessions to acquire responding, and as long as needed until criteria were met (rarely more than 5 sessions; criteria: ≥20 reinforcers earned per session, with <20% variation over two sessions and ≥70% active responses) After acquisition criteria were met, water was substituted for at least three sessions and until responding was extinguished to <50% of each mouse’s food-maintained responding.

An indwelling catheter was then implanted into the right or left external jugular vein under oxygen/sevoflorane vapor anesthesia. The surgical procedure has been described in detail (Thomsen & Caine, 2005). Briefly, a catheter (Silastic tubing 0.2 mm inner diameter, 0.4 mm outer diameter) was inserted 1.2 cm into the jugular vein and delicately anchored to the vein. The catheter ran subcutaneously to the base located above the midscapular region. The mice were allowed 7 days recovery, during which 0.02 ml of 0.9% saline containing heparin (30 USP units/ml) and antibiotic (cefazoline, 67 mg/ml) was infused daily through the catheter to forestall clotting and infection. After the post-operative recovery period, catheters were flushed with saline containing heparin immediately before and after self-administration sessions, and the free end of the cannula guide was kept closed at all times. Catheter patency was confirmed before initiation of cocaine self-administration and after completion of each dose-effect determination by the infusion of 0.02-0.03 ml of 1% brevital in saline. Loss of muscle tone and clear signs of anesthesia within 3 sec of infusion indicated catheter patency.

After recovery, mice were again introduced to the operant conditioning chambers for 3-hr sessions, 5 days/week, and allowed to self-administer 1.0 mg/kg/infusion cocaine i.v. under the same FR 1 schedule as above. Criteria for stable cocaine self-administration were the same as for food, followed by saline substitution until extinction criteria were met (<50% of cocaine responding). Cocaine dose-effect functions were determined in each mouse according to a Latin square design, 0.032-1.0 mg/kg/infusion. Then dose-effect functions were determined again in the same manner, but with each session preceded by administration of a muscarinic agonist. In some mice, 3.2 mg/kg/infusion cocaine was tested last, without
then with pretreatment. Finally, liquid food was again substituted as the reinforcer for two sessions, first with no pretreatment, then with the same muscarinic agonist tested with cocaine, in each mouse.

**Drugs.** Cocaine hydrochloride was supplied by the National Institute on Drug Abuse (National Institutes of Health, Bethesda, MD). D-amphetamine sulfate, scopolamine hydrobromide, (-)-scopolamine methylbromide (methylscopolamine), oxotremorine sesquifumarate, McN-A-343 ((4-Hydroxy-2-butynyl)-1-trimethylammonium-3-chlorocarbanilate chloride) and S(-)-eticlopride were purchased from Sigma-Aldrich (St. Louis, MO). Pilocarpine hydrochloride and (+/-)-U-50488 (trans-(±)-3,4-Dichloro-N-methyl-N-[2-(1-pyrroolidinyl)cyclohexyl]benzeneacetamide) hydrochloride were purchased from Tocris (Ellisville, MO). TBPB (1-(1-2-methylbenzyl)-1,4-bipiperidin-4-yl)-1H benzo[d]imidazol-2(3H)-one) was synthesized at the Vanderbilt University. Xanomeline was synthesized at the McLean Hospital according to previously published methods (Kane et al., 2008). TBPB and U-50488 were dissolved in double deionized water, and eticlopride was dissolved in ethanol followed by dilution in sterile water (final concentration ethanol 1%). All other drugs were dissolved in sterile 0.9% saline. All drug doses refer to the weights of the respective salts.

**Data analysis.** For the drug discrimination assay, % drug appropriate responding (DAR) for the whole session and total response rates (i.e., responses in both holes combined) are presented. In all cases comparable effects were observed in %DAR for the first reinforcer (not shown) The common occurrence of missing values for %DAR, due to complete suppression of behavior by the test drugs, precluded the use of ANOVA on %DAR. Effects were thus analyzed by comparing A₅₀ values in cocaine dose-effect functions with and without the test drug. For A₅₀ calculations, the doses estimated to produce 50% DAR (substitution tests), 50% decrease in DAR (pretreatment tests) and 50% decrease in response rates (all tests), were estimated in each mouse by interpolation of the dose-effect curves, then group means and 95% confidence intervals were calculated. Effects on response rates were analyzed by repeated measures ANOVA with drug dose as factor. For cocaine self-administration dose-effect functions, data from the first two hours of the sessions were analyzed and presented. This time frame was chosen based on time-course data obtained on the pretreatment drugs using a mouse operant rate assay in our laboratory. The numbers of reinforcers earned were compared using repeated measures ANOVA with cocaine dose and pretreatment as factors. Significant effects were followed where appropriate by
Bonferroni-corrected two-sided paired-sample t-tests. Food reinforcers earned under baseline and pretreatment conditions were compared by two-sided paired-sample t-test. Significance level was set at $p < 0.05$ before Bonferroni correction.

For isobolographic analysis, the %DAR dose-effect functions for cocaine, scopolamine, and methylscopolamine were fitted by non-linear regression using the equation $E = (E_{\text{max}} \cdot A^p) / (A^p + A_{50}^p)$, where $E$ denotes the effect, $A$ the dose, $E_{\text{max}}$ the maximal effect achieved by the drug in question, $A_{50}$ the dose estimated to elicit 50% of this maximal effect, and $p$ is a factor related to the slope of the curve (“Hill coefficient”). The individual data for all mice, rather than means, were used for curve-fitting, and 95% confidence limits were also obtained. Curve fitting was executed using GraphPad Prism v. 4.0 for Mac. The equations were then rearranged to express dose as a function of effect: $A = ((E \cdot A_{50}^p) / (E_{\text{max}} - E))^{1/p}$.

Thus the equivalent (equieffective) doses of each drug was calculated, and expected additive DAR values (with 95% confidence limits) were computed by adding the dose cocaine equivalent to 0.32 mg/kg of scopolamine, or 1 mg/kg of methylscopolamine to each dose of cocaine tested, and entering this total dose into the cocaine equation. 95% confidence limits for each drug (i.e., cocaine and either scopolamine or methylscopolamine) were obtained, but only the largest (most conservative) interval for each data point are reported for brevity.
Results

Baseline cocaine discrimination behavior and control tests

Swiss-Webster mice met criteria for cocaine discrimination after on average 15.1 ± 1.3 weeks (range, 6-31 weeks). Figure 1 shows cocaine dose-effect determinations in all mice from which data are reported in the present investigation. Cocaine produced DAR in a dose-dependent manner, reaching 100% in all mice. Positive and negative controls were established with the psychostimulant amphetamine and the kappa agonist U-50488, respectively, as shown in Figure 1 and Table 1. Amphetamine reached 100% DAR in all mice, while no appreciable DAR was observed after U-50488 treatment up to a dose that almost eliminated responding (peak DAR in any subject: 3%). Table 1 shows the doses estimated to produce 50% DAR and 50% reduction in response rate (relative to saline) for each drug.

Effects of muscarinic receptor antagonists in the cocaine discrimination assay

As shown in Figure 2, scopolamine and methylscopolamine both substituted partially for cocaine, (scopolamine peak: 44 ± 17% DAR at 3.2 mg/kg, methylscopolamine peak: 63 ± 18% at 32 mg/kg; mean ± s.e.m). Methylscopolamine was significantly less potent than scopolamine (see Table 1), consistent with its poorer penetration of the blood-brain barrier. Neither drug significantly affected response rate, but 56 mg/kg methylscopolamine resulted in the death of the first mice tested, and evaluation of this dose was therefore discontinued.

Figure 3 shows that the addition of 0.32 mg/kg scopolamine to cocaine produced a moderate leftward shit in the dose-effect curve, which was significant based on non-overlapping 95% confidence intervals for cocaine’s A₅₀ values: cocaine alone, 1.95 [1.19 – 3.19] mg/kg; cocaine + scopolamine, 0.64 [0.42 – 0.97] mg/kg. Scopolamine alone at 0.32 mg/kg did not engender any DAR (0-1% in individual mice). Response rate was not significantly affected by either cocaine or scopolamine dose. The addition of 1.0 mg/kg methylscopolamine produced a more pronounced leftward shift, so that a lower cocaine dose was added in order to enable A₅₀ calculations (0.1 mg/kg, tested last). The effect of methylscopolamine addition was significant based on non-overlapping 95% confidence intervals for cocaine’s A₅₀ values: cocaine alone, 1.91 [1.12 – 3.26] mg/kg; cocaine + methylscopolamine, 0.38 [0.18 –
0.83] mg/kg. Methylscopolamine alone at 1 mg/kg did not engender any appreciable DAR (0-3% in individual mice). Response rate was not significantly affected by either cocaine or methylscopolamine dose.

Table 2 shows the results of isobolographic analysis of the cocaine + scopolamine and the cocaine + methylscopolamine combinations. The calculated dose cocaine equivalent to 0.32 mg/kg scopolamine was 0.409 mg/kg, 95% confidence limits 0.003 – 0.207 mg/kg. The calculated dose cocaine equivalent to 1 mg/kg methylscopolamine was 0.431 mg/kg, 95% confidence limits 0.007-0.754 mg/kg. In both cases, the expected dose-effect curve if simple additivity was assumed did not differ significantly from the experimentally determined cocaine-alone curves (data not shown). In contrast, comparison of cocaine alone to the experimentally determined drug combinations indicated that the combination was significantly more potent than expected for additivity, at least for portions of the curve (see Table 2).

Effects of muscarinic receptor agonists in the cocaine discrimination assay

Figure 4 shows the effects on %DAR (top panels) and response rate (bottom panels) of pretreatment with the non-selective muscarinic agonists pilocarpine and oxotremorine, the M₁/M₄-preferring agonist xanomeline, the novel M₁-selective agonist TBPB, and the non-brain penetrant M₁ agonist McN-A-343.

Pilocarpine had little effect on %DAR but decreased response rates \( F_{4,32} = 85.9, \ p < 0.0001 \). Oxotremorine produced a 50% decrease in DAR, but also suppressed response rates \( F_{3,24} = 30.9, \ p < 0.0001 \), so that only four mice emitted responses at the highest dose. Of those, two emitted responses only in the cocaine-appropriate hole, and two emitted responses only in the saline-appropriate hole. Potencies for suppression of DAR and response rates are shown in Table 3, significance of post-hoc tests on rate are shown in Fig. 4. Xanomeline decreased DAR by up to 60% (peak effect at 1.8 mg/kg), but also suppressed response rates as a function of dose \( F_{4,32} = 21.5, \ p < 0.0001 \). TBPB decreased DAR by 37% at 32 mg/kg while higher doses had little effect on DAR. Response rates decreased with dose TBPB \( F_{4,28} = 9.7, \ p < 0.0001 \). McN-A-343 had little effect on DAR, as only 2 of 9 mice showed decreases at the highest dose. Pretreatment to a range of cocaine doses in those two mice were not indicative of rightward shifts, rather produced mixed results more consistent with a masking effect or loss of stimulus control (data not shown). Although doses up to 18 mg/kg did not affect response rates
significantly, higher doses were not tested because a pilot experiment with 32 mg/kg resulted in lack of responding and/or death in 2 of 4 mice tested.

We then assessed whether pretreatment with 0.1 mg/kg oxotremorine, 1.0 or 1.8 mg/kg xanomeline, or 32 mg/kg TBPB could produce a rightward shift in cocaine’s %DAR dose-effect function. Figure 5 shows cocaine dose-effect functions with and without pretreatment (within-subjects). Oxotremorine produced a 3-fold rightward shift, which was not statistically significant based on overlapping 95% confidence intervals (see Table 4). However this dose oxotremorine suppressed response rates [F₁,₃₅ = 58.9, p < 0.0001] (no significant effect of cocaine dose, no interaction; see Fig. 5 for significant effects post-hoc). Xanomeline produced a significant 5- to 7-fold shift in the cocaine DAR curve. Response rates were also decreasing by both 1.0 mg/kg xanomeline [F₁,₂₅ = 16.1, p < 0.001] and 1.8 mg/kg xanomeline [F₁,₃₅ = 47.5, p < 0.0001], although decrease reached significance post-hoc only at the 1.8 mg/kg pretreatment dose. TBPB produce a comparable rightward shift but did not affect response rates.

To test the hypothesis that the muscarinic agonists attenuated cocaine’s discriminative stimulus by a M₁ and/or M₄ receptor-dependent mechanism, we tested xanomeline (1.0, 1.8, 3.2 mg/kg) in knockout mice lacking M₁ and M₄ receptors. Both wild-type C57BL/6Ntac mice and M₁⁻/-M₄⁻/- mice acquired cocaine discrimination (DAR under saline test, mean ± s.e.m: wild-type and M₁⁻/-M₄⁻/-, respectively: 1.2% ± 0.6, 0.5% ± 0.5; 10 mg/kg cocaine test 99.1% ± 0.3, 99.4% ± 0.4; N of 4 to 9). In the wild-type mice, xanomeline decreased DAR similarly to its effects in Swiss Webster mice, but in the M₁⁻/-M₄⁻/- mice xanomeline had no effect on DAR (Figure 6). However xanomeline showed similar rate-suppressing effect in wild-type mice ([F₃,₁₅ = 10.4, p < 0.001]; A₅₀ with 95% confidence limits: 2.36 mg/kg [2.22-2.50]), and in M₁⁻/-M₄⁻/- mice ([F₃,₆ > 100, p < 0.0001]; A₅₀ 2.48 mg/kg [2.36-2.61]).

We also tested, in Swiss-Webster mice, whether the cocaine-like stimulus produced by a muscarinic antagonist (methylscopolamine) could be blocked by muscarinic agonist pretreatments (oxotremorine, TBPB; Figure 7). Oxotremorine produced a rightward shift in DAR, and profoundly decreased response rates [F₁,₂₈ > 100, p < 0.001]. Post hoc comparisons indicated significant reductions in rate for all methylscopolamine doses (p < 0.05 to p < 0.001 vs. methylscopolamine alone), with a trend for saline (p = 0.06). The mean decrease in response rates was -78% [95% confidence limits: -91% to -66%]. TBPB decreased DAR across methylscopolamine doses (only one mouse emitted >10% DAR in the
pretreatment condition), but did not affect response rates significantly. Meaningful mean A50 values could not be estimated in the pretreatment conditions, due to numerous missing values (i.e., failure to respond) in the case of oxotremorine, and due to failure to reach 50% DAR in the case of TBPB.

Comparison to dopamine antagonist pretreatment in the cocaine discrimination assay

As a positive control for the pretreatment effects, we tested the dopamine D2 antagonist eticlopride as pretreatment to cocaine (Figure 8). Eticlopride decreased DAR by up to 75%, and decreased response rates profoundly in the same dose range [F5,40 = 26.0, p < 0.0001].

We then evaluated eticlopride pretreatment, 0.032 and 0.1 mg/kg, over the range of cocaine doses. Both doses of eticlopride produced significant 4- or 5-fold rightward shifts in the DAR curve (see also Table 4). While the lower dose did not decrease response rate significantly, 0.1 mg/kg did [F1,35 = 68.3, p < 0.0001], with a significant eticlopride by cocaine interaction [F4,35 = 2.8, p < 0.05].

Effects of muscarinic receptor agonists in cocaine self-administration

We also tested muscarinic agonists in mice that self-administered i.v. cocaine chronically. Under baseline conditions, cocaine was self-administered in all three groups of mice with inverted U-formed dose-effect functions typical for the FR 1 schedule of reinforcement. This was confirmed by significant effects of cocaine dose (oxotremorine group [F4,20 = 12.0, p < 0.0001], xanomeline group [F4,28 = 6.0, p < 0.01], TBPB group [F4,28 = 15.3, p < 0.0001]). In each group, 0.1 and 0.32 mg/kg/infusion cocaine were self-administered above saline levels (p < 0.05 to 0.01 vs. saline; Figure 9, top panels). Pretreatment with oxotremorine (0.032 mg/kg), xanomeline (1 mg/kg) or TBPB (32 mg/kg) each abolished cocaine self-administration. Repeated measures ANOVA confirmed a significant effect of treatment for oxotremorine [F1,5 = 15.1, p < 0.05], xanomeline [F1,7 = 35.8, p < 0.001], and TBPB [F1,7 = 41.7, p < 0.001], as well as significant cocaine dose by pretreatment interactions ([F4,20 = 14.7, p < 0.0001], [F4,28 = 5.3, p < 0.01], and [F4,28 = 9.8, p < 0.0001], respectively). After agonist pretreatment cocaine did not maintain significant self-administration at any dose.

For comparison, the same mice were tested using the same operant procedure reinforced with a palatable liquid food instead of cocaine (Figure 9, bottom panels). Oxotremorine decreased food-
reinforced responding \( (p < 0.05) \), although the magnitude of effect was smaller than for cocaine. Xanomeline produced a small, non-significant decrease in food-reinforced behavior \( (p = 0.15) \), and TBPB did not affect food-reinforced behavior \( (p > 0.7) \). Oxotremorine was also tested at doses of 0.032 and 0.1 mg/kg as pretreatment to a full range of liquid food dilutions in water, using the same methods (See Supplemental Figure 1 online). Oxotremorine produced parallel downward shifts in the food concentration-effect curves. ANOVA with food concentration and dose oxotremorine as repeated measures factors confirmed an effect of food concentration \( [F_{4,24} = 36.3, p < 0.0001] \) and dose oxotremorine \( [F_{2,12} = 18.5, p < 0.001] \), with no interaction.
We examined muscarinic modulation of the discriminative and reinforcing effects of cocaine in mice. Swiss-Webster mice readily acquired and maintained cocaine discrimination in a standard two-manipulandum procedure. Control experiments with amphetamine and a kappa agonist confirmed pharmacological specificity of the training stimulus. We found that muscarinic antagonists enhanced, and muscarinic agonists decreased, the discriminative stimulus of cocaine in a manner consistent with involvement of M₁ receptors.

Our findings with scopolamine and methylscopolamine confirm and extend previous studies in rats, in which atropine and scopolamine produced leftward shifts in cocaine’s discriminative stimulus (Acri et al., 1996; Katz et al., 1999; Tanda & Katz, 2007). In male Sprague-Dawley rats trained to discriminate 10 mg/kg cocaine from saline, muscarinic antagonists produced little or no cocaine-appropriate responding (Katz et al., 1999; Tanda & Katz, 2007), or partial substitution comparable to the present findings (Acri et al., 1996). Thus, rather than a species difference, it appears that subtle differences using comparable assays (e.g., behavioral or pharmacological history of the subjects) can modify the response to muscarinic antagonists. This is consistent with a weak cocaine-like discriminative stimulus, or a stimulus only partially overlapping with cocaine. Tanda and Katz (2007) showed similar leftward shifts in cocaine discrimination with the M₁- or M₁/M₄ preferring antagonists telenzepine and trihexyphenidyl, and suggested that M₁ receptors mediated at least part of those “cocaine-enhancing” effects. Telenzepine and trihexyphenidyl also increased cocaine-induced increases in extracellular NAc dopamine, providing some clues as to the mechanism of this modulation (Tanda et al., 2007). Consistent with this finding, the lower potency of methylscopolamine relative to scopolamine in the present investigation suggests a centrally mediated cocaine-like stimulus of the muscarinic antagonists. Our data also suggested a more-than-additive effect of combining muscarinic antagonists with cocaine. This is consistent with observations of increased effects of cocaine in the absence of appreciable effects of the antagonists alone in some previous studies (Katz et al., 1999; Tanda & Katz, 2007, Tanda et al., 2007).

To the best of our knowledge, modulation of cocaine’s discriminative stimulus by muscarinic agonists has not been described previously. In the present study, oxotremorine produced some reduction in DAR,
but only at doses that dramatically decreased response rates. Pilocarpine appeared to have little effect on DAR up to doses that eliminated responding. The rate-suppressing effects of both drugs make it difficult to evaluate any effect on DAR, so that the apparent difference in effects between oxotremorine and pilocarpine may not be reproducible or biologically meaningful. Alternatively, the observed results could reflect differences between the two drugs’ relative efficacies to activate muscarinic receptor subtypes, as several investigations indicated (e.g., Leiber et al., 1990). The putative non brain-penetrant M1 agonist McN-A-343 had little effect on DAR, up to doses approaching toxicity. The selectivity of McN-A-343 has been debated, but recent data using muscarinic M1-/- mice supported the notion that McN-A-343 is functionally selective for the M1 receptor in vivo (Hardouin et al., 2002; Kremin et al., 2006). McN-A-343 is a quaternary ammonium structure, thought to penetrate the blood-brain barrier poorly (Walland et al., 1997). Although it cannot be excluded that higher doses may have affected DAR, a pilot experiment indicated a quarter log increase above the highest dose tested would be lethal in some mice, which is consistent with observations in guinea pigs (Walland et al., 1997). Thus, as with the muscarinic antagonists, the relative lack of effect of McN-A-343 on DAR is consistent with a centrally mediated effect of the muscarinic agonists on cocaine discrimination.

The M1/M4-preferring agonist xanomeline produced clear shifts in the cocaine discrimination curve, at doses that produced low to moderate rate suppression. The novel M1-selective agonist TBPB produced a comparable rightward shift at a dose that did not affect response rate. Thus M1 receptor stimulation appears sufficient to attenuate cocaine’s discriminative stimulus. This finding is also in agreement with the recent finding that TBPB can attenuate amphetamine-induced locomotor stimulation (Jones et al., 2008). Interestingly, TBPB lost its effectiveness at higher doses in the present study, presumably due to some antagonist activity at muscarinic non-M1 receptors (unpublished observations), suggesting a possible contribution of other subtypes in “anti-cocaine” effects. Further supporting the role of M1/M4 receptors in mediating these “anti-cocaine” effects, xanomeline failed to decrease DAR in the M1-/-M4-/- double knockout mice up to a dose that nearly eliminated responding. Interestingly, xanomeline decreased response rates comparably in both genotypes, indicating that rate-decreasing effects were mediated through non-M1/M4 muscarinic receptors. Xanomeline has moderate functional selectivity for M1/M4 subtypes over M2/M3 subtypes, which are the primary subtypes in peripheral tissues (Shannon et al.,
We speculate that M₂ and/or M₃ receptor stimulation accounts for most of the rate suppression observed with less selective muscarinic agonists, and that selective M₁ or M₁/M₄ agonists may have a low incidence of side effects typically associated with non-selective muscarinic agonists in humans.

For comparison with the muscarinic agonists, we tested the dopamine D₂ receptor antagonist eticlopride in the cocaine discrimination assay. Eticlopride dose-dependently reduced DAR and produced rightward shifts in the cocaine dose-effect function, as seen previously in monkeys (Spealman, 1996). The magnitude of shift in cocaine DAR was comparable to that obtained with xanomeline and TBPB, up to a dose of eticlopride that almost eliminated responding when tested alone. Some mutual antagonism was apparent, as might be expected, as increasing doses of cocaine attenuated the rate suppressing effects of eticlopride, up to a certain point. To our knowledge, the muscarinic agonists therefore produced as large an effect in the cocaine discrimination assay as any other pharmacological manipulation reported. We also verified that muscarinic agonists could attenuate the cocaine-like stimulus induced by a muscarinic antagonist, suggesting a common (reciprocal) mechanism of action for muscarinic manipulations enhancing and antagonizing the discriminative stimulus of cocaine, such as modulation of cocaine-induced increases in extracellular dopamine (see above, and Tanda & Katz, 2007).

In addition to cocaine’s discriminative stimulus, we assessed whether muscarinic agonists could blunt the reinforcing effects of cocaine, by testing them in mice that self-administered i.v. cocaine chronically. We found that pretreatment with oxotremorine, xanomeline or TBPB abolished cocaine self-administration. Thus the muscarinic agonists blocked the reinforcing effects of cocaine more completely than they affected its discriminative stimulus. While oxotremorine also decreased food-maintained responding, xanomeline had little or no effect on food-maintained behavior and TBPB had no effect on food-maintained behavior under the conditions studied. Although the difference in baseline rates of responding maintained by food and somewhat limits the conclusions that can be drawn from this comparison, experiments with lower food reinforcer magnitudes suggested that at oxotremorine’s effects on operant behavior was not dependent on ongoing rates of responding. In a previous report, intra-NAc infused oxotremorine reduced cocaine self-administration in rats but had no appreciable effect on food-maintained behavior (Mark et al., 2006). This effect was blocked by the M₁-preferring antagonist...
pirenzepine (Mark et al., 2006). Our findings extend those results in that systemically administered oxotremorine similarly reduced cocaine self-administration, but also produced non-specific rate suppression. Taken together, previous and present findings suggest two things. First, stimulation of M₁ receptors in the NAc (with or without participation of M₄ receptors) accounts for most or all of the muscarinic agonist-induced suppression of abuse-related effects of cocaine. Second, these effects can be observed in the absence of undesirable non-specific effects by using M₁-selective ligands.

TBPB has moderate affinity for D₂ receptors (Jones et al., 2008), raising the concern that its effects might result from D₂ receptor blockade. However, 100 mg/kg TBPB showed no D₂ occupancy in a PET study in rats (Jones et al., 2008), and oxotremorine and xanomeline have no or low dopamine receptor affinities (Burt et al., 1975; Shannon et al., 1994). Furthermore, results of the knockout experiment are inconsistent with a role of D₂ receptors in the observed effects of the muscarinic agonists. Importantly, the modulation of cocaine self-administration by muscarinic agonists is qualitatively different from the effects of dopamine antagonists, which produce reciprocal and surmountable antagonism, manifested by rightward shifts in cocaine dose-effect functions in mice (Caine et al., 2002). Here we saw no increase in self-administration of high cocaine doses, even when 3.2 mg/kg/infusion cocaine was tested in some mice (data not shown). Taken together, those findings indicate that direct dopamine receptor antagonism did not significantly contribute to the muscarinic agonist modulation of cocaine’s behavioral effects. Furthermore, our data suggest muscarinic agonists modulate abuse-related effects of cocaine in a more complex fashion than simply through functional dopamine antagonism.

In summary, we extended previous findings that muscarinic antagonists can produce partial substitution in animals trained to discriminate cocaine from saline, can synergistically enhance the discriminative stimulus of cocaine, and that these effects are most likely mediated through central muscarinic receptors. More importantly, we found that muscarinic agonists can blunt the discriminative stimulus of cocaine and abolish cocaine self-administration behavior, and that these effects are likely mediated in part or completely through striatal M₁ receptors. Finally, we found that the M₁-selective agonist TBPB produced no suppression of food-maintained operant behaviors, suggesting that novel, highly M₁-selective agonists may have a low incidence of adverse effects in humans. Collectively, these findings raise the possibility of an entirely new approach to pharmacological treatments for cocaine...
addiction. Further studies are warranted to establish whether those “anti-cocaine” effects of M₃/M₄ agonists can be generalized to other strains, species, schedules of reinforcement and, importantly, chronic treatments. Future studies may also better elucidate the involvement of each receptor subtype in both muscarinic agonist-induced blunting of cocaine’s discriminative stimulus and reinforcing effects (e.g., M₁, M₄), and in undesirable effects of muscarinic agonists (e.g., M₂, M₃).
Acknowledgements

We thank Jennifer Dohrmann and Dana Angood for technical assistance. We thank Dr. Carrie K. Jones for help coordinating between sites.
References


Chapman CA, Yeomans JS, Blaha CD and Blackburn JR (1997) Increased striatal dopamine efflux follows scopolamine administered systemically or to the tegmental pedunculopontine nucleus. *Neuroscience* **76**:177-186.

receptors in the nucleus accumbens core is necessary for the acquisition of drug reinforcement. *J Neurosci* **26**:6004-10.


Footnotes:

The present work was supported by the National Institutes of Health (National Institute on Drug Abuse and National Institute of Mental Health) [grants DA007252, DA-012142, MH-073676, MH-082867]. MT was supported in part by a NARSAD Young Investigator Award and a Eleanor and Miles Shore / Harvard Medical School Fellowship during this work.

Part of this work was presented at the annual meeting of the International Study Group Investigating Drugs As Reinforcers in Reno, NV, June 20, 2009.

Current address for BSF: Center for Drug Discovery, Northeastern University, 360 Huntington Avenue, Boston, MA 02115
Legends for Figures

Figure 1:
Effects of cocaine, d-amphetamine and the kappa agonist U-50488 in mice trained to discriminate cocaine from saline. Abscissae: drug dose in mg/kg, “V” indicates vehicle. Ordinates: %cocaine-appropriate responses (top panel), response rate in responses per second (bottom panel). Data are groups means ± sem. Groups sizes: cocaine: N = 30, amphetamine: N = 7, U-50488: N = 6. In the top panel, exceptions to these group sizes are indicated on the figure when some mice failed to respond at the highest drug doses. **p < 0.01 vs. vehicle.

Figure 2:
Substitution of the muscarinic receptor antagonists scopolamine or methylscopolamine. Abscissae: drug dose in mg/kg, “V” indicates vehicle. Ordinates: %cocaine-appropriate responses (top panel), response rate in responses per second (bottom panel). Data are groups means ± sem; N = 8, except 56 mg/kg methylscopolamine: N = 5.

Figure 3:
Combinations of cocaine with scopolamine or methylscopolamine. Abscissae: cocaine dose in mg/kg, “Sal” indicates saline. Ordinates: %cocaine-appropriate responses (top panel), response rate in responses per second (bottom panel). Data are groups means ± sem. Groups sizes: cocaine/scopolamine: N = 9, cocaine/methylscopolamine: N = 8.

Figure 4:
Effects of various muscarinic receptor agonists as pretreatment to 10 mg/kg cocaine. Abscissae: muscarinic agonist dose in mg/kg, “V” indicates vehicle. Ordinates: %cocaine-appropriate responses (top panel), response rate in responses per second (bottom panel). Data are groups means ± sem. Groups sizes: TBPB: N = 8, all other: N = 9. Exceptions to these group sizes are indicated on the figure when
some mice failed to respond at a particular drug dose and were not tested on a higher dose, when applicable. *p < 0.05, **p < 0.01, ***p < 0.001 vs. saline.

**Figure 5:**

**Effects of muscarinic agonist pretreatments on the cocaine dose-effect function.** Abscissae: cocaine dose in mg/kg, “Sal” indicates saline. Ordinates: %cocaine-appropriate responses (top panel), response rate in responses per second (bottom panel). Data are groups means ± sem. Groups sizes: oxotremorine and TBPB: N = 8, xanomeline: N = 9. Exceptions to these group sizes are indicated on the figure when some mice failed to respond at a particular drug dose. *p < 0.05, **p < 0.01 vs. cocaine alone.

**Figure 6:**

**Effects of xanomeline pretreatment in M1-/-M4-/- and wild-type mice.** Abscissae: xanomeline dose in mg/kg, “V” indicates vehicle. Ordinates: %cocaine-appropriate responses (top panel), response rate in responses per second (bottom panel). Data are groups means ± sem. Groups sizes: M1-/-M4-/-: N = 3, Wild-type: N = 6. Exceptions to these group sizes are indicated on the figure when some mice failed to respond at a particular drug dose and were not tested on a higher dose.

**Figure 7:**

**Effects of muscarinic agonist pretreatments in methylscopolamine substitution.** Abscissae: methylscopolamine dose in mg/kg, “Sal” indicates saline. Ordinates: %cocaine-appropriate responses (top panel), response rate in responses per second (bottom panel). Data are groups means ± sem. Groups sizes (Swiss-Webster mice): oxotremorine: N = 8, TBPB: N = 6. Exceptions to these group sizes are indicated on the figure when some mice failed to respond at a particular drug dose. *p < 0.05, ***p < 0.001 vs. methylscopolamine alone.

**Figure 8:**
Effects of dopamine D<sub>2</sub> receptor antagonist pretreatment to cocaine. Abscissae: Eticlopride dose in microgram/kg (left panels, “V” indicates pretreatment vehicle; all as pretreatment to 10 mg/kg cocaine), cocaine dose in mg/kg (right panels, “Sal” indicates saline). Ordinates: %cocaine-appropriate responses (top panel), response rate in responses per second (bottom panel). Data are groups means ± sem. Groups sizes (Swiss-Webster mice): eticlopride dose-effect and 0.032 mg/kg: N = 9, eticlopride 0.1 mg/kg: N = 8. Exceptions to these group sizes are indicated on the figure when some mice failed to respond at a particular drug dose and were not tested on a higher dose, when applicable. **p < 0.01, ***p < 0.001 vs. cocaine alone.

Figure 9:

Effects of muscarinic agonist pretreatments in cocaine intravenous self-administration and food-maintained operant behavior. Abscissae: cocaine dose in mg/kg/infusion (top panels, “Sal” indicates saline), treatment (bottom panels). Ordinates: number of cocaine infusions earned in 2 hr (top panel), number of food reinforcers earned in 2 hr (bottom panel). Data are groups means ± sem. Groups sizes (Swiss-Webster mice): oxotremorine: N = 6, xanomeline and TBPB: N = 8. *p < 0.05, **p < 0.01 vs. saline; #p < 0.05, ##p < 0.01 vs. baseline.
Table 1: Substitutions

<table>
<thead>
<tr>
<th>Pretreatment (dose)</th>
<th>$A_{50}$ DAR</th>
<th>N/N</th>
<th>$A_{50}$ rate reduction</th>
<th>N/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cocaine</td>
<td>1.96 [1.46 – 2.64]</td>
<td>29/29</td>
<td>not calculated</td>
<td>4/29</td>
</tr>
<tr>
<td>Amphetamine</td>
<td>0.33 [0.22 – 0.54]</td>
<td>7/7</td>
<td>not calculated</td>
<td>3/7</td>
</tr>
<tr>
<td>U-50488</td>
<td>not applicable</td>
<td>0/6</td>
<td>9.32 [6.25 – 13.90]</td>
<td>6/6</td>
</tr>
<tr>
<td>Scopolamine</td>
<td>0.90 [0.29 – 2.76]</td>
<td>4/8</td>
<td>not calculated</td>
<td>3/8</td>
</tr>
</tbody>
</table>

N/N indicates the number of mice showing ≥ 50% reduction in %DAR and ≥ 50% reduction in response rates, respectively, over number of mice tested.
Table 2: Predicted additive and experimentally determined dose of cocaine needed to produce a given effect level in combination with 0.32 mg/kg scopolamine or 1 mg/kg methylscopolamine

The dose cocaine needed to produce 30 to 95% DAR in the mouse discrimination assay were calculated from non-linear curve-fitting of the dose-effect functions, both as predicted if cocaine/scopolamine and cocaine/methylscopolamine combinations were additive, and calculated directly from the experimentally determined drug mixture dose-effect functions. Both antagonists enhanced the discriminative stimulus of cocaine in a more-than additive manner at some effect levels.

<table>
<thead>
<tr>
<th>Effect level</th>
<th>Cocaine/scopolamine mixture</th>
<th>Cocaine/methylscopolamine mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Predicted additive</td>
<td>Actual</td>
</tr>
<tr>
<td>30</td>
<td>0.88 [0.53 - 1.36]</td>
<td>0.53 [0.35 - 0.71]</td>
</tr>
<tr>
<td>40</td>
<td>1.25 [0.79 - 1.90]</td>
<td>0.63 [0.44 - 0.86]</td>
</tr>
<tr>
<td>50</td>
<td>1.65 [1.07 - 2.50]</td>
<td>0.75 [0.54 - 1.03]</td>
</tr>
<tr>
<td>80</td>
<td>3.66 [2.32 - 6.02]</td>
<td>1.32 [0.95 - 1.90]</td>
</tr>
</tbody>
</table>

*non-overlapping 95% CL relative to predicted additive. All doses calculated in mg/kg, effect levels are in %DAR.
Table 3: Pretreatment-induced decreases in DAR and rate, with 10 mg/kg cocaine

The dose of each pretreatment drug estimated to produce 50% reduction in DAR, and the dose estimated to produce 50% reduction in response rate (relative to vehicle) are shown as group mean [95% confidence interval] of values calculated in each mouse. N/N indicates the number of mice showing ≥ 50% reduction in DAR and ≥ 50% reduction in response rates, respectively, over number of mice tested (the first N thus represents the number of mice from which A50 values were calculated). Means were not calculated when an A50 could be calculated in less than half the mice tested.

<table>
<thead>
<tr>
<th>Pretreatment drug</th>
<th>$A_{50}$ DAR reduction</th>
<th>N/N (DAR)</th>
<th>$A_{50}$ rate reduction</th>
<th>N/N (rate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxotremorine</td>
<td>not calculated</td>
<td>3/9</td>
<td>0.07 [0.05 – 0.10]</td>
<td>9/9</td>
</tr>
<tr>
<td>Xanomeline</td>
<td>1.08 [0.78 – 1.50]</td>
<td>6/9</td>
<td>1.98 [1.59 – 2.45]</td>
<td>8/9</td>
</tr>
<tr>
<td>TBPB</td>
<td>not calculated</td>
<td>3/9</td>
<td>67.73 [55.27 – 83.01]</td>
<td>7/8</td>
</tr>
<tr>
<td>McN-A-343</td>
<td>not calculated</td>
<td>2/9</td>
<td>not calculated</td>
<td>2/8</td>
</tr>
<tr>
<td>Eticlopride</td>
<td>0.05 [0.02 – 0.10]</td>
<td>6/9</td>
<td>0.11 [0.07 – 0.18]</td>
<td>9/9</td>
</tr>
</tbody>
</table>
Table 4: Pretreatment-induced cocaine dose-effect function shifts

The dose cocaine estimated to produce 50% DAR, as group mean of values calculated in each mouse [95% confidence interval], was significantly higher after all but the oxotremorine treatment, which produced a smaller, non-significant rightward shift. Fold shift indicates the $A_{50}$ after pretreatment divided by the baseline $A_{50}$, as group mean and 95% confidence interval of shifts calculated in each mouse.

<table>
<thead>
<tr>
<th>Pretreatment (dose)</th>
<th>$A_{50}$ cocaine alone</th>
<th>$A_{50}$ pretreatment</th>
<th>Fold shift</th>
<th>Mean rate decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xanomeline (1.0)</td>
<td>1.22 [0.61 – 2.44]</td>
<td>5.76 [3.36 – 9.88]*</td>
<td>5.5 [2.8 – 8.3]</td>
<td>-28% [-45% – -10%]</td>
</tr>
<tr>
<td>Xanomeline (1.8)</td>
<td>1.16 [0.69 – 1.94]</td>
<td>5.32 [2.86 – 9.90]*</td>
<td>7.0 [2.3 – 11.7]</td>
<td>-51% [-67% – -35%]</td>
</tr>
<tr>
<td>TBPB (32)</td>
<td>1.43 [0.86 – 2.37]</td>
<td>7.30 [4.04 – 13.20]*</td>
<td>6.7 [4.3 – 9.1]</td>
<td>+ 6% [-15% – +5%]</td>
</tr>
<tr>
<td>Eticlopride (0.032)</td>
<td>1.10 [0.78 – 1.74]</td>
<td>4.39 [2.70 – 7.13]*</td>
<td>5.4 [0.9 – 9.8]</td>
<td>- 4% [- 9% – +17%]</td>
</tr>
<tr>
<td>Eticlopride (0.1)</td>
<td>1.10 [0.78 – 1.74]</td>
<td>4.45 [2.15 – 9.21]*</td>
<td>4.3 [2.6 – 6.1]</td>
<td>-70% [-87% – -53%]</td>
</tr>
</tbody>
</table>

* non-overlapping 95% confidence intervals relative to cocaine alone.
Figure 1

% cocaine-appropriate

Responses / s

Substitution drug dose [mg/kg]
Figure 3

![Graph showing the effects of different cocaine doses on response rates.](image-url)
Figure 4

Oxotremorine

Pilocarpine

Xanomeline

TBPB

McN-A-343

% cocaine-appropriate

Responses/s

Dose muscarinic agonist [mg/kg]

V 0.03 0.1 0.18
V 1 3.2 5.6 10
V 0.3 1 1.8 3.2 5.6 10 100
V 3.2 10 18

* * * * * * * *
Figure 5

Oxotremorine

- Cocaine alone
- +0.1 mg/kg oxotremorine

Xanomeline

- +1 mg/kg xanomeline
- +1.8 mg/kg xanomeline

TBPB

- +32 mg/kg TBPB

% cocaine-appropriate

Responses/s

Dose cocaine [mg/kg]

Sal 1 3.2 10 18

Sal 1 3.2 10 18

Sal 1 3.2 10 18
Figure 7

% cocaine-appropriate

Responses/s

Methylyscopolamine dose [mg/kg]

Sal 3.2 10 32

Sal 3.2 10 32
Figure 8
Figure 9

Oxotremorine  
Xanomeline  
TBPB

Cocaine infusions earned

Dose cocaine [mg/kg/infusion]

Food reinforcers earned

Baseline  oxo. 0.03 mg/kg  
Baseline  xano. 1.0 mg/kg  
Baseline  TBPB 32 mg/kg